First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
Open, Non Controlled, Multicenter, First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer
Sponsor: GamaMabs Pharma
A PHASE1 clinical study on Neoplasm, Gynecologic, this trial is completed. The trial is conducted by GamaMabs Pharma and has accumulated 9 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Oct 2021 — May 2022 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 4 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GamaMabs Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Besançon, France , Bordeaux, France , Brussels, Belgium , Leuven, Belgium , Lille, France , London, United Kingdom , Lyon, France , Montpellier, France , Nancy, France , Paris, France and 2 more locations